Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Cited In for PubMed (Select 9722920)

1.

Characterization of CD8+ T cell differentiation following SIVΔnef vaccination by transcription factor expression profiling.

Billingsley JM, Rajakumar PA, Connole MA, Salisch NC, Adnan S, Kuzmichev YV, Hong HS, Reeves RK, Kang HJ, Li W, Li Q, Haase AT, Johnson RP.

PLoS Pathog. 2015 Mar 13;11(3):e1004740. doi: 10.1371/journal.ppat.1004740. eCollection 2015 Mar.

2.

A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.

Rabinovich S, Powell RL, Lindsay RW, Yuan M, Carpov A, Wilson A, Lopez M, Coleman JW, Wagner D, Sharma P, Kemelman M, Wright KJ, Seabrook JP, Arendt H, Martinez J, DeStefano J, Chiuchiolo MJ, Parks CL.

PLoS One. 2014 Sep 12;9(9):e106597. doi: 10.1371/journal.pone.0106597. eCollection 2014.

3.

Challenges in mucosal HIV vaccine development: lessons from non-human primate models.

Tuero I, Robert-Guroff M.

Viruses. 2014 Aug 15;6(8):3129-58. doi: 10.3390/v6083129. Review.

4.

Location and dynamics of the immunodominant CD8 T cell response to SIVΔnef immunization and SIVmac251 vaginal challenge.

Sasikala-Appukuttan AK, Kim HO, Kinzel NJ, Hong JJ, Smith AJ, Wagstaff R, Reilly C, Piatak M Jr, Lifson JD, Reeves RK, Johnson RP, Haase AT, Skinner PJ.

PLoS One. 2013 Dec 9;8(12):e81623. doi: 10.1371/journal.pone.0081623. eCollection 2013.

5.

Delivery strategies for novel vaccine formulations.

Trovato M, Krebs SJ, Haigwood NL, De Berardinis P.

World J Virol. 2012 Feb 12;1(1):4-10. doi: 10.5501/wjv.v1.i1.4.

6.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. Print 2013.

7.

Envelope determinants of equine lentiviral vaccine protection.

Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC.

PLoS One. 2013 Jun 13;8(6):e66093. doi: 10.1371/journal.pone.0066093. Print 2013.

8.

Mucosal immunology of HIV infection.

Xu H, Wang X, Veazey RS.

Immunol Rev. 2013 Jul;254(1):10-33. doi: 10.1111/imr.12072. Review.

9.

Correlates of relative resistance against low-dose rectal simian immunodeficiency virus challenges in peripheral blood mononuclear cells of vaccinated rhesus macaques.

Kurupati R, Tuyishime S, Kossenkov AV, Sazanovich M, Haut LH, Lasaro MO, Ratcliffe SJ, Bosinger SE, Carnathan DG, Lewis M, Showe LC, Silvestri G, Ertl HC.

J Leukoc Biol. 2013 Mar;93(3):437-48. doi: 10.1189/jlb.0612287. Epub 2012 Dec 27.

10.

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.

Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD 3rd, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M Jr, Lifson JD, Sékaly RP, Picker LJ.

Nat Med. 2012 Nov;18(11):1673-81. doi: 10.1038/nm.2934. Epub 2012 Sep 9.

11.

Modelling the spread of HIV immune escape mutants in a vaccinated population.

Fryer HR, McLean AR.

PLoS Comput Biol. 2011 Dec;7(12):e1002289. doi: 10.1371/journal.pcbi.1002289. Epub 2011 Dec 1.

12.

Characterization of an effective CTL response against HIV and SIV infections.

Genescà M.

J Biomed Biotechnol. 2011;2011:103924. doi: 10.1155/2011/103924. Epub 2011 Sep 29. Review.

13.

New paradigms for HIV/AIDS vaccine development.

Picker LJ, Hansen SG, Lifson JD.

Annu Rev Med. 2012;63:95-111. doi: 10.1146/annurev-med-042010-085643. Epub 2011 Sep 19. Review.

14.

Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.

Bilello JP, Manrique JM, Shin YC, Lauer W, Li W, Lifson JD, Mansfield KG, Johnson RP, Desrosiers RC.

J Virol. 2011 Dec;85(23):12708-20. doi: 10.1128/JVI.00865-11. Epub 2011 Sep 7.

15.

Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.

Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC.

Vaccine. 2010 Nov 29;28(51):8095-104. doi: 10.1016/j.vaccine.2010.10.003. Epub 2010 Oct 16.

16.

Possible applications for replicating HIV 1 vectors.

Das AT, Jeeninga RE, Berkhout B.

HIV Ther. 2010 May 1;4(3):361-369.

17.

HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Das AT, Berkhout B.

Philos Trans R Soc Lond B Biol Sci. 2010 Jun 27;365(1548):1965-73. doi: 10.1098/rstb.2010.0072. Review.

18.

Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Greene JM, Lhost JJ, Burwitz BJ, Budde ML, Macnair CE, Weiker MK, Gostick E, Friedrich TC, Broman KW, Price DA, O'Connor SL, O'Connor DH.

J Virol. 2010 Apr;84(7):3362-72. doi: 10.1128/JVI.02028-09. Epub 2010 Jan 20.

19.

Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.

Willer DO, Guan Y, Luscher MA, Li B, Pilon R, Fournier J, Parenteau M, Wainberg MA, Sandstrom P, MacDonald KS.

J Virol. 2010 Mar;84(5):2304-17. doi: 10.1128/JVI.01995-09. Epub 2009 Dec 23.

20.

Disruption of an env tyrosine-dependent sorting signal does not affect susceptibility of HIV-1 to cytotoxic T lymphocytes.

Cruz Jde L, Ali A, Ng HL, Yang OO.

AIDS. 2009 Jul 17;23(11):1449-51. doi: 10.1097/QAD.0b013e32832dbf91. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk